Syneos Health's Value and Access team recently discussed with MM&M a range of issues impacting the pharmaceutical industry's approach to product pricing and commercialization. Pat Leary, executive vice president of clinical field teams and market access and deployment solutions, tells MM&M […]
Measure Creating Drug Pricing Board Becomes Law
A measure passed by state legislators in Maryland to create the nation's first drug affordability board became law today, July 1, according to a STAT report. The Prescription Drug Affordability Board will have the power to cap how much state and local governments pay for prescription drugs. […]
Newly-Released Emails Shed More Light into Alleged Price-Fixing Scheme
A new batch of emails made public by the Connecticut Attorney General's office this week revealed how a lawyer for Heritage Pharmaceuticals attempted to coordinate with other drugmakers for a response to a Congressional inquiry, The Middletown Press reports. "In early October 2014, Heritage […]
Article Looks at Big Pharma’s Lawsuit on TV Ad Rule
A recent article by American Council on Science and Health Senior Medical Fellow Charles Dinerstein highlights a recent lawsuit filed be three pharmaceutical companies fighting the Trump administration's mandate which requires drugmakers to include a drug's list price in television ads. Amgen, […]
States Eye Massachusetts’ Plan to Wrangle Drug Costs
States are keeping a close eye on Massachusetts as it attempts to wrangle prescription drug spending in its MassHealth program, The Meadville Tribune reports. According to the report, Massachusetts Gov. Charlie Baker proposed giving power to health officials to post a drug's value if it's found to […]
Drugmakers Suing Trump White House Over Ad Mandate
Drugmakers Amgen, Merck and Eli Lilly are suing the Trump administration over its recent rule requiring pharmaceutical companies to include a drug's list price in television ads, STAT reports. The Association of National Advertisers is also involved in the lawsuit, according to the report. Amgen […]
Podcast Highlights Potential Implications of HHS Rebate Proposal
A recent Relentless Health Value podcast shifts the spotlight on what Health and Human Services' (HHS) rebate proposal could mean for pharmaceutical companies and pharmacy benefit managers. The podcast features Capital Rx CEO Anthony Loiacono. "Since any middleman who gets himself involved in any […]
FTI Consulting Working with Pfizer on Drug Pricing
FTI Consulting is reportedly working with pharmaceutical giant Pfizer on drug pricing matters, according to a Consulting.us report. Few details were provided in the report regarding the scope of the arrangement. Pfizer is one of 20 organizations involved in a massive lawsuit led by Connecticut […]
Optum: These Five Drugs to Have Major Impact on Market
Onasemnogene abeparvovec, NKTR-181, golodirsen, upadacitinib and tafamidis meglumine are poised to have a significant impact on the drug market, according to a new OptumRx report. Novartis' Zolgensma, a gene therapy for spinal muscular atrophy, was the latest drug to hit the market with tremendous […]
Report: ICER Seeing Rising Influence as Pricing Debates Continue
The Institute for Clinical and Economic Review (ICER) continues to gain traction in the drug pricing discussion as a growing number of stakeholders look to the organization for drug pricing benchmarks, according to a Managed Care magazine report. According to the report, ICER has a full slate this […]
